Relmada Therapeutics, Inc.
NASDAQ:RLMD · NASDAQ Global Select
+$0.13 today
Vol 2.02M · Avg 1.21M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-66.3%
avg -107.9%
ROIC
-67.5%
avg -108.6%
ROA
-61.0%
avg -115.7%
Analysis
ROA is currently the strongest return metric at -61.0% versus its period average of -115.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Sergio Traversa | Chief Executive Officer & Director | $3.94M | — | 66 | $1.30M | 1.77% |
Maged S. Shenouda | Chief Financial Officer | $2.64M | — | 62 | $800,000.00 | 1.09% |
Charles S. Ence | Chief Accounting & Compliance Officer | $2.17M | — | 61 | $828,000.00 | 1.13% |
Paul E. Kelly | Chief Operating Officer & Director | $1.96M | — | 69 | $828,000.00 | 1.13% |
Andrew Cutler | Senior Clinical Development Advisor | — | — | — | — | — |
Raj S. Pruthi | Chief Medical Officer of Urology | — | — | 59 | — | — |
Richard Mangano | Consultant | — | — | 76 | — | — |
Gina DiGuglielmo | Vice President & Head of Clinical Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
9
$2.54M
Sells
0
$0.00
Net Sentiment
+$2.54M
Net buying
Most Active
TRAVERSA SERGIO
5 transactions
Analysis
Insiders reported 9 buys worth $2.54M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $2.54M. TRAVERSA SERGIO was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Immunic, Inc.
NASDAQ:IMUX
$136.78M
Vaxart, Inc.
NASDAQ:VXRT
$135.55M
Repare Therapeutics Inc.
RPTX
$114.24M
Fortress Biotech, Inc.
NASDAQ:FBIO
$92.02M
Adicet Bio, Inc.
NASDAQ:ACET
$75.25M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$59.20M
Cibus, Inc.
NASDAQ:CBUS
$55.95M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$55.71M
Acrivon Therapeutics, Inc. Common Stock
ACRV
$46.70M
Lite Strategy, Inc.
LITS
$25.22M
Who manages RLMD?
Relmada Therapeutics, Inc. (RLMD) lists 8 active executives. The top listed executive is Andrew Cutler, Senior Clinical Development Advisor.
Are RLMD insiders buying or selling?
Recent insider activity shows net buying of $81.59M.
Explore More
Continue the stock analysis
Jump to another research area for this company.